Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations - Scorecard - MDSpire
Advertisement
Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations
Clinical Scorecard: Exploring Cardiovascular Benefits of SGLT2 Inhibitors: A Comprehensive Review of Mechanisms, Clinical Findings, and Safety Aspects
At a Glance
Category
Detail
Condition
Cardiovascular Disease
Key Mechanisms
Multilayered network of systemic, metabolic, vascular, and cellular mechanisms.
Target Population
Patients with heart failure (HFrEF and HFpEF), type 2 diabetes mellitus, and non-diabetic populations.
Care Setting
Clinical settings for cardiovascular disease management.
Key Highlights
SGLT2 inhibitors provide cardiovascular and cardiorenal benefits beyond glycemic control.
Empagliflozin and dapagliflozin show robust prognostic benefits in heart failure.
Cardioprotective effects arise from interconnected mechanisms, not solely glucose lowering.
Emerging evidence suggests potential reduction in atrial fibrillation or flutter risk.
Safety considerations include genital infections, volume depletion, and renal function changes.
Guideline-Based Recommendations
Diagnosis
Assess cardiovascular disease risk in patients with type 2 diabetes and heart failure.
Management
Consider SGLT2 inhibitors for cardiovascular protection in heart failure patients.
Monitoring & Follow-up
Monitor renal function and signs of volume depletion in patients on SGLT2 inhibitors.
Risks
Be aware of potential adverse effects such as euglycemic ketoacidosis and genital infections.
Patient & Prescribing Data
Patients with an estimated glomerular filtration rate (eGFR) of ≥60 mL/min/1.73 m2 for dapagliflozin, or ≥45 mL/min/1.73 m2 for canagliflozin and empagliflozin.
Therapeutic efficacy declines with progressive renal impairment.
Clinical Best Practices
Incorporate SGLT2 inhibitors into treatment plans for eligible patients with heart failure.
Evaluate individual patient profiles for personalized treatment approaches.
